Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Blood ; 139(14): 2212-2226, 2022 04 07.
Artículo en Inglés | MEDLINE | ID: mdl-35061876

RESUMEN

Non-Hispanic Black (NHB) and Hispanic patients with acute myeloid leukemia (AML) have higher mortality rates than non-Hispanic White (NHW) patients despite more favorable genetics and younger age. A discrete survival analysis was performed on 822 adult patients with AML from 6 urban cancer centers and revealed inferior survival among NHB (hazard ratio [HR] = 1.59; 95% confidence interval [CI]: 1.15, 2.22) and Hispanic (HR = 1.25; 95% CI: 0.88, 1.79) patients compared with NHW patients. A multilevel analysis of disparities was then conducted to investigate the contribution of neighborhood measures of structural racism on racial/ethnic differences in survival. Census tract disadvantage and affluence scores were individually calculated. Mediation analysis of hazard of leukemia death between groups was examined across 6 composite variables: structural racism (census tract disadvantage, affluence, and segregation), tumor biology (European Leukemia Network risk and secondary leukemia), health care access (insurance and clinical trial enrollment), comorbidities, treatment patterns (induction intensity and transplant utilization), and intensive care unit (ICU) admission during induction chemotherapy. Strikingly, census tract measures accounted for nearly all of the NHB-NHW and Hispanic-NHW disparity in leukemia death. Treatment patterns, including induction intensity and allogeneic transplant, and treatment complications, as assessed by ICU admission during induction chemotherapy, were additional mediators of survival disparities in AML. This is the first study to formally test mediators for observed disparities in AML survival and highlights the need to investigate the mechanisms by which structural racism interacts with known prognostic and treatment factors to influence leukemia outcomes.


Asunto(s)
Leucemia Mieloide Aguda , Racismo Sistemático , Adulto , Etnicidad , Disparidades en el Estado de Salud , Hispánicos o Latinos , Humanos , Leucemia Mieloide Aguda/terapia , Población Blanca
2.
Biol Blood Marrow Transplant ; 24(5): 997-1004, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29288821

RESUMEN

Haplo/cord transplantation combines an umbilical cord blood (UCB) graft with CD34-selected haploidentical cells and results in rapid hematopoietic recovery followed by durable UCB engraftment. We compared outcomes of transplants in older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) who received either HLA-matched unrelated donor (MUD) cells or haplo/cord grafts. Between 2007 and 2013, 109 adults ages 50 and older underwent similar reduced-intensity conditioning with fludarabine and melphalan and antibody-mediated T cell depletion for AML (n = 83) or high-risk MDS (n = 26) followed by either a MUD (n = 68) or haplo/cord (n = 41) graft. Patient characteristics were similar for each graft source except for more minority patients receiving a haplo/cord transplant (P = .01). One half of the AML patients were not in remission. Two-year progression-free survival (PFS), overall survival (OS), and graft-versus-host disease-free relapse-free survival were 38%, 48%, and 32.1% for MUD and 33%, 48%, and 33.8% for haplo/cord transplants (P = .62 for PFS; P = .97 for OS; P= .84), respectively. Acute grades II to IV and chronic graft-versus-host-disease rates did not differ at 19.5% and 4.9% in haplo/cord compared with 25% and 7.4% after MUD (P = .53 and P = .62, respectively). Multivariate analysis confirmed no significant differences in transplant outcomes by donor type. Haplo/cord reduced-intensity transplantation achieves similar outcomes relative to MUD in older AML and MDS patients, making this a promising option for those without matched donors.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Leucemia Mieloide Aguda/terapia , Síndromes Mielodisplásicos/terapia , Acondicionamiento Pretrasplante/métodos , Anciano , Antígenos CD34/sangre , Femenino , Sangre Fetal/trasplante , Enfermedad Injerto contra Huésped/etiología , Trasplante de Células Madre Hematopoyéticas/mortalidad , Trasplante de Células Madre Hematopoyéticas/normas , Prueba de Histocompatibilidad , Humanos , Leucemia Mieloide Aguda/mortalidad , Depleción Linfocítica , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/mortalidad , Análisis de Supervivencia , Acondicionamiento Pretrasplante/mortalidad , Trasplante Haploidéntico , Donante no Emparentado
3.
Biol Blood Marrow Transplant ; 22(6): 1065-1072, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26912055

RESUMEN

Delayed engraftment and cord graft failure (CGF) are serious complications after unrelated cord blood (UCB) hematopoietic stem cell transplantation (HSCT), particularly when using low-cell-dose UCB units. The haplo-cord HSCT approach allows the use of a lower dose single UCB unit by co-infusion of a CD34(+) selected haploidentical graft, which provides early transient engraftment while awaiting durable UCB engraftment. We describe the frequency, complications, and risk factors of CGF after reduced-intensity conditioning haplo-cord HSCT. Among 107 patients who underwent haplo-cord HSCT, 94 were assessable for CGF, defined as <5% cord blood chimerism at day 60 in the myeloid and CD3 compartments, irrespective of neutrophil and platelet counts. CGF occurred in 14 of 94 assessable patients (15%). Median survival after CGF was 12.7 months with haploidentical or mixed haploidentical-autologous hematopoiesis persisting in the 7 surviving. Median progression-free survival after CGF was 7.7 months and was not statistically different from those without CGF (10.47 months; P = .18). In univariate analyses, no UCB factors were associated with CGF, including cell dose, cell viability, recipient major ABO mismatch against the UCB unit, or degree of HLA match. We also found no association of CGF with recipient cytomegalovirus serostatus, haploidentical donor age, or day 30 haploidentical chimerism. However, higher haploidentical total nucleated and CD34(+) cell doses and day 30 UCB chimerism < 5% in either the myeloid or CD3 compartments were associated with greater risk of CGF. We conclude that assessing chimerism at day 30 may foretell impending CGF, and avoidance of high haploidentical cell doses may reduce risk of CGF after haplo-cord HSCT. However, long-term survival is possible after CGF because of predominant haploidentical or mixed chimerism and hematopoietic function.


Asunto(s)
Trasplante de Células Madre de Sangre del Cordón Umbilical/métodos , Sangre Fetal/citología , Rechazo de Injerto/prevención & control , Haploidia , Acondicionamiento Pretrasplante/métodos , Adolescente , Adulto , Anciano , Antígenos CD34 , Quimerismo , Trasplante de Células Madre de Sangre del Cordón Umbilical/efectos adversos , Trasplante de Células Madre de Sangre del Cordón Umbilical/mortalidad , Femenino , Rechazo de Injerto/etiología , Histocompatibilidad , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Análisis de Supervivencia , Trasplante Haploidéntico/métodos , Adulto Joven
5.
Med Care ; 47(1): 41-7, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19106729

RESUMEN

BACKGROUND: Efforts to enhance patient-physician communication may improve management of underdiagnosed chronic conditions. Patient internet portals offer an efficient venue for coaching patients to discuss chronic conditions with their primary care physicians (PCP). OBJECTIVES: We sought to test the effectiveness of an internet portal-based coaching intervention to promote patient-PCP discussion about chronic conditions. RESEARCH DESIGN: We conducted a randomized trial of a nurse coach intervention conducted entirely through a patient internet-portal. SUBJECTS: Two hundred forty-one patients who were registered portal users with scheduled PCP appointments were screened through the portal for 3 target conditions, depression, chronic pain, mobility difficulty, and randomized to intervention and control groups. MEASURES: One-week and 3-month patient surveys assessed visit experiences, target conditions, and quality of life; chart abstractions assessed diagnosis and management during PCP visit. RESULTS: Similar high percentages of intervention (85%) and control (80%) participants reported discussing their screened condition during their PCP visit. More intervention than control patients reported their PCP gave them specific advice about their health (94% vs. 84%; P = 0.03) and referred them to a specialist (51% vs. 28%; P = 0.002). Intervention participants reported somewhat higher satisfaction than controls (P = 0.07). Results showed no differences in detection or management of screened conditions, symptom ratings, and quality of life between groups. CONCLUSIONS: Internet portal-based coaching produced some possible benefits in care for chronic conditions but without significantly changing patient outcomes. Limited sample sizes may have contributed to insignificant findings. Further research should explore ways internet portals may improve patient outcomes in primary care. ClinicalTrials.gov registration NCT00130416.


Asunto(s)
Enfermedad Crónica/terapia , Comunicación , Medicina Familiar y Comunitaria/métodos , Internet/estadística & datos numéricos , Educación del Paciente como Asunto/métodos , Relaciones Médico-Paciente , Atención Primaria de Salud/métodos , Consulta Remota/métodos , Centros Médicos Académicos , Adulto , Anciano , Anciano de 80 o más Años , Citas y Horarios , Boston , Enfermedad Crónica/clasificación , Depresión/diagnóstico , Depresión/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Limitación de la Movilidad , Relaciones Enfermero-Paciente , Evaluación de Procesos y Resultados en Atención de Salud , Dolor/diagnóstico , Manejo del Dolor , Calidad de Vida , Adulto Joven
7.
Aging Cell ; 6(2): 209-24, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17376146

RESUMEN

Among vertebrates, fish and mammals show intriguing differences in their growth control properties with age. The potential for unlimited or indeterminate growth in a variety of fish species has prompted many questions regarding the senescent phenomena that appear during the aging process in these animals. Using zebrafish as our model system, we have attempted in our current study to examine the growth phenomena in fish in relation to the onset of senescence-associated symptoms, and to evaluate the effects of genotoxic stress on these processes. We observed in the course of these analyses that the zebrafish undergoes continuous growth, irrespective of age, past the point of sexual maturation with gradually decreasing growth rates at later stages. Animal population density, current body size and chronological age also play predominant roles in regulating zebrafish growth and all inversely influence the growth rate. Interestingly, the induction of genotoxic stress by exposure to ionizing radiation (IR) did not adversely affect this body growth ability in zebrafish. However, IR was found to chronically debilitate the regeneration of amputated caudal fins and thereby induce high levels of abnormal fin regeneration in the adult zebrafish. In addition, by resembling and mimicking the natural course of aging, IR treatments likewise enhanced several other symptoms of senescence, such as a decline in reproductive abilities, increased senescence-associated beta-galactosidase activity and a reduction in melatonin secretion. Our current data thus suggest that during the lifespan of zebrafish, the onset of senescence-associated symptoms occurs in parallel with continuous growth throughout mid-adulthood. Moreover, our present findings indicate that genotoxic DNA damage may play a role as a rate-limiting factor during the induction of senescence, but not in the inhibition of continuous, density-dependent growth in adult zebrafish.


Asunto(s)
Envejecimiento/genética , Daño del ADN/fisiología , Pez Cebra/crecimiento & desarrollo , Envejecimiento/fisiología , Animales , Encéfalo/metabolismo , Encéfalo/efectos de la radiación , Femenino , Branquias/fisiología , Branquias/efectos de la radiación , Masculino , Melatonina/metabolismo , Fenotipo , Radiación Ionizante , Regeneración , Reproducción , beta-Galactosidasa/metabolismo
8.
J Gen Intern Med ; 23(4): 472-5, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18373147

RESUMEN

BACKGROUND: Patient Internet portals have created new opportunities for assessment and management of chronic conditions. OBJECTIVE: To conduct an online screening survey for a study recruitment using a secure patient Internet portal to identify primary care patients with untreated depression, chronic pain, or mobility difficulty before nonurgent office visits. DESIGN: Internet-based screening survey for a randomized trial. PARTICIPANTS: Patients who were registered portal users who had scheduled primary care appointments. APPROACH: Electronic study invitations via the portal were sent to 4,047 patients with scheduled visits to 34 primary care physicians participating in the study. After clicking on a link in the study invitation, patients were consecutively shown the study description, consent form, and lastly, the screening survey to determine final eligibility for study participation. RESULTS: Of the 2,113 (52%) patients who opened the study invitation, 1,001 consented online to join the study and 981 (98%) of these completed the screening survey. Of the respondents, 319 (33%) screened positive for 1 or more of the 3 conditions. CONCLUSIONS: The online screening survey conducted through the patient portal was effective in identifying patients with chronic conditions in advance of scheduled primary care visits for participation in an intervention study.


Asunto(s)
Enfermedad Crónica , Encuestas Epidemiológicas , Internet , Tamizaje Masivo/métodos , Selección de Paciente , Adulto , Enfermedad Crónica/terapia , Depresión/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor/métodos , Relaciones Médico-Paciente , Médicos de Familia , Atención Primaria de Salud
9.
Exp Gerontol ; 38(7): 777-86, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12855287

RESUMEN

The zebrafish (Danio rerio) has been developed as a powerful model for genetic studies in developmental biology, which also gives insights into several diseases of adult humans such as cardiovascular disease and cancer. Because aging processes affect these and many other human diseases, it is important to compare zebrafish and other mammalian aging. However, the aging process of zebrafish remains largely unexplored, and little is known about its functional aging and senescence. In a survey of aging in zebrafish, we detected senescence-associated beta-galactosidase activity in skin and oxidized protein accumulation in muscle. However, we did not observe lipofuscin granules ('aging pigments'), which commonly accumulate in postmitotic cells of other vertebrates. This absence of lipofuscins may be consistent with the existence of continuously proliferating myocytes that incorporated BrdU in muscle tissues of aged zebrafish. Moreover, we demonstrated that zebrafish have constitutively abundant telomerase activity in somatic tissues from embryos to aged adults. Although some stress-associated markers are upregulated and minor histological changes are observed during the aging process of zebrafish, our studies together with other evidence of remarkable reproductive and regenerative abilities suggest that zebrafish show very gradual or sub-negligible senescence in vivo.


Asunto(s)
Envejecimiento/fisiología , Modelos Animales , Pez Cebra/fisiología , Animales , Biomarcadores/análisis , Bromodesoxiuridina/metabolismo , División Celular , Lipofuscina/análisis , Músculos/citología , Músculos/metabolismo , Oxidación-Reducción , Poecilia/fisiología , Proteínas/metabolismo , Piel/enzimología , Especificidad de la Especie , Telomerasa/metabolismo , Vertebrados/fisiología , beta-Galactosidasa/análisis
10.
Amyloid ; 18(3): 160-4, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21504342

RESUMEN

In AL (amyloid light-chain) amyloidosis, the greatest risk of death occurs in patients with cardiac involvement, who typically develop diastolic dysfunction and then systolic heart failure, with predisposition to arrhythmias and sudden death. Here, we present an alternate variation of cardiac amyloidosis. This patient had recent non-obstructive coronary angiography, yet suffered a fatal myocardial infarction shortly after stem cell collection and mobilization in preparation for treatment with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). On autopsy, widespread deposition of amyloid was found in the small vessels of the heart with evidence of associated acute infarction. While the typical presentation of cardiac amyloidosis is an infiltrating restrictive cardiomyopathy, this case report and literature review illustrate that ischemic small vessel amyloidosis may also occur. Small vessel coronary disease and associated myocardial ischemia should be considered in patients with AL amyloidosis with angina, as its presence may increase treatment-related complications. Contemporary testing should aim to detect both forms of cardiac amyloidosis, which may impact management and prognosis.


Asunto(s)
Amiloide/metabolismo , Amiloidosis/patología , Vasos Coronarios/patología , Mieloma Múltiple/patología , Infarto del Miocardio/patología , Amiloidosis/complicaciones , Amiloidosis/metabolismo , Autopsia , Vasos Coronarios/diagnóstico por imagen , Vasos Coronarios/metabolismo , Ecocardiografía , Resultado Fatal , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/complicaciones , Mieloma Múltiple/metabolismo , Mieloma Múltiple/terapia , Infarto del Miocardio/etiología , Infarto del Miocardio/metabolismo , Miocardio/metabolismo , Miocardio/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA